<DOC>
	<DOCNO>NCT02749513</DOCNO>
	<brief_summary>The purpose study demonstrate orally administer itraconazole , commonly use antifungal medication , inhibit Hedgehog pathway signal patient esophageal cancer , include adenocarcinoma ( EAC ) squamous cell carcinoma ( ESCC ) .</brief_summary>
	<brief_title>Itraconazole Targeted Therapy Inhibiting Hedgehog Pathway Signaling Esophageal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>â€¢ Clinical diagnosis esophageal cancer , include gastroesophageal junction cancer Patients unwilling unable provide inform consent Coagulopathy preclude safe endoscopic/surgical procedure ( platelet count &lt; 100,000/mm3 , INR &gt; 1.5 ) Esophageal varix Comorbidity ( e.g . pulmonary , cardiac , renal , liver disease ) preclude safe participation study QTc &gt; 450 m LFT 's &gt; 3xULN Pregnancy Allergy itraconazole History symptomatic congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>